logo
Sign in or Register

Already a member?

Sign in

Or sign in with your account on:

Not a member yet?

Register
    

Retrophin Raises Offer to Acquire Transcept Pharmaceuticals to $4 Per Share

By  +Follow September 19, 2013 8:51AM
Share:
Tickers Mentioned:

Retrophin, Inc. (RTRX) is not giving up on its pursuit to acquire the shares of specialty drug maker Transcept Pharmaceuticals, Inc. (TSPT) that it does not already own.  Last week, Retrophin delivered a letter to the board of directors of Transcept offering to buy the remaining shares for $3.50 each in cash.  The offer was rejected. 

To defend itself from a hostile takeover, Transcept has adopted a shareholder rights plan, often called a “poison pill,” which keeps a shareholder from acquiring more than 4.99 percent of the company.

On Wednesday, Retrophin bumped the offer up to $4.00 per share, with Retrophin chief executive Martin Shkreli sending a letter to the board members of Transcept.

Transcept is focused on development of neuroscience drugs with its only FDA approval being the oral sleep aid Intermezzo (zolpidem tartrate).  Purdue Pharma holds commercialization and development right for Intermezzo in the U.S.  Royalty revenue for Transcept from Intermezzo in the first six months of 2013 was $1.0 million, up from $500,000 in the year prior period. 

Net loss for the six months ended June 30, 2013 was approximately $17.2 million, or $0.92 per share, versus a net loss of approximately $10.3 million, or $0.67 per share, for the six months of 2012.

Retrophin has four drugs in its pipeline with RE-021 the only one in the clinical stage, being researched in a mid-stage trial for Focal Segmental Glomerulosclerosis, a disease that can cause nephrotic syndrome in children and kidney failure in adults.  The company’s other compounds are targeting hard-to-treat diseases like Pantothenate Kinase-Associated Neurodegeneration (PKAN) and Duchenne Muscular Dystrophy.

In recent weeks, three major shareholders of Transcept have publicly stated their disapproval of Transcept’s current strategy.  Activist investor Peter Collery of SC Fundamental LLC, which owns a 6.7-percent stake in Transcept, sent a letter to Transcept chief executive, president and director Glenn Oclassen (read the SEC filing) saying that the company needs to use $60 million of its cash to conduct a share repurchase to build value, not pursue “simply wrongheaded,” (but unnamed) projects.

Collery didn’t hold back much in expressing his feelings toward Transept management.  Such as:

“I should note how troubled we are by your presumption that the company’s money is yours to do with as you see fit. You and your fellow directors have a fiduciary duty to company shareholders.”

And...

“I’d like, in closing, also to express my displeasure with the company’s recent grant of nearly 600,000 management stock options with a strike price of $2.93 per share. As described above, the company’s shares may have a current realizable value of $5 or so. Were Transcept to implement a buyback program, that value might rise to $6. Essentially no management skill would be required to realize these values. That the shares trade for less than $3 is a function of shareholders’ distrust of management. It is incredible that management should be granted undervalued stock options as a “reward” for having created that distrust and I would expect that an inquiry into the deliberations surrounding this recent option grant, and particularly, the suitability of the strike price would be quite interesting.”

Roumell Asset Management, LLC, the largest Transcept shareholder at 12.3 percent of the company, has also filed a 13D with the SEC criticizing the management and demanding a share buy-back plan, not an unidentified acquisition.

The new proposal by Retrophin offers to buy Transcept at a 20-percent premium to Tuesday’s closing price.  The price is still lower than the $6 mark that Collery believes can be attained by performing a share repurchase, but this is a little to-may-toes/to-ma-toes because a merged company could benefit similarly, so investors will have to see where the support falls with the new proposal.

“Our proposal represents an attractive premium to Transcept’s trading performance, and we believe that the proposal offers a compelling opportunity for Transcept’s stockholders, particularly in light of Transcept’s risky and controversial acquisition strategy,” stated Martin Shkreli, Chief Executive Officer of Retrophin. “We hope that Transcept’s Board of Directors will respect its stockholders’ wishes and quickly commence discussions with us regarding the proposed transaction.”

Retrophin wants a transaction to be entered into by the end of September.

Shares of TSPT are down about 18 percent in 2013 thanks to a run-up from lows of $2.52 late in August with the acquisition chatter.  At lows, the stock was off about 40 percent.  Shares rose by 8 percent in Wednesday trading to close at $3.59.  In extended trading, shares rose to $3.98.  Retrophin shares edged up about 1 percent on the day to $6.88.  Shares have more than doubled in 2013.

Results for rtrx
Pzaa...Guy
23 Apr 14 05:04:26
$RTRX - Organizational Transitions, Patient Enrollment, Initiation of Clinical Programs, Financial Outlook, and http://t.co/L2iM7rHKrO
Gold Stock News
23 Apr 14 02:31:56
$RTRX Should You Get Rid of Retrophin (RTRX) No http://t.co/W7DmRB6ORy
Leighton Aldaine
23 Apr 14 01:55:46
$RTRX Should You Get Rid of Retrophin (RTRX) No http://t.co/vtE2j1tkSr
Stockaholics
22 Apr 14 22:46:45
Members saw 5,000% gains on Penny Stock Alert's in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Stockaholics
22 Apr 14 19:40:51
Our Penny Stock Newsletter Picks, Gained 5,000% in 4.5 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Yahaira Landry
22 Apr 14 18:29:37
$RTRX Should You Get Rid of Retrophin (RTRX http://t.co/OjCnJLfsrA
Hui Veal
22 Apr 14 17:27:25
$RTRX Should You Get Rid of Retrophin (RTRX http://t.co/EJsuLxMvqg
Insider Trade Alerts
22 Apr 14 16:04:36
$RTRX Should You Get Rid of Retrophin (RTRX) No http://t.co/M5mOYpl0T8
Lt. Dunbar
22 Apr 14 15:30:15
$RTRX continues its bounce off 11.40. bullish engulfing pattern- can run higher IMO
Stock Occulus
22 Apr 14 14:41:43
$RTRX Should You Get Rid of Retrophin (RTRX http://t.co/uWsCf5xarO
Fin_Vestor
22 Apr 14 14:38:21
$RTRX Stock On Radar: Retrophin Inc And Energy Recovery Inc http://t.co/V7vi7IQ1ao
Stockaholics
22 Apr 14 12:24:25
Our Penny Stock Newsletter Picks, Gained 5,000% in 4.5 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Pawcio
22 Apr 14 11:40:47
Looks like $rtrx finally decided to join the biotech party.
Stockaholics
22 Apr 14 09:23:31
Our Penny Stock Newsletter Picks, Gained 5,000% in 4.5 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Alfred Jaxon
22 Apr 14 06:48:50
$RTRX Should You Get Rid of Retrophin (RTRX http://t.co/wiPQtOy4cb
M
22 Apr 14 06:17:57
RT @edmundsullivan: $RTRX RT @MartinShkreli: 024: FDA reportedly "largely satisfied" with safety/efficacy data in IND. Minor questions on s…
GavinGreenberg
22 Apr 14 06:02:34
$RTRX: Should You Get Rid of Retrophin (RTRX) Now? http://t.co/XmIgRnvDvN
StockNews24
22 Apr 14 05:51:42
$RTRX - Should You Get Rid of Retrophin (RTRX) Now? -> http://t.co/e4ExJi4juQ #stock #stocks #stockaction
Edmund Sullivan
22 Apr 14 04:55:24
$RTRX RT @MartinShkreli: 024: FDA reportedly "largely satisfied" with safety/efficacy data in IND. Minor questions on solubility, stability.
Stockaholics
21 Apr 14 20:49:53
After 5,000% gains, our New SECRET Penny Stock Alert, is coming today! Check it out: http://t.co/jrft0mERif $RTRX $CPST $TGTX
Carpe DM, Inc.
21 Apr 14 17:09:18
@montana_jp I think you'll have several opportunities. This should be pretty volatile for the next few months. Take a look at $RTRX.
Stockaholics
21 Apr 14 16:22:44
After 5,000% gains, our New SECRET Penny Stock Alert, is coming today! Check it out: http://t.co/jrft0mERif $RTRX $CPST $TGTX
Kulsrud Brothers
21 Apr 14 16:18:13
RT @vram2000: Given $SRPT, should orphan drug co's play a more active role in galvanizing support from patients/members of congress @Martin…
Stockaholics
21 Apr 14 13:14:12
After 5,000% gains, our New SECRET Penny Stock Alert, is coming today! Check it out: http://t.co/jrft0mERif $RTRX $CPST $TGTX
BioInvestor
21 Apr 14 12:15:55
Given $SRPT, should orphan drug co's play a more active role in galvanizing support from patients/members of congress @MartinShkreli $RTRX
Stockaholics
21 Apr 14 08:57:03
Our Penny Stock Newsletter Picks, gained 5,000% in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Eric Shaw
21 Apr 14 06:29:29
My watch list: $WB $SRPT $MU $SNDK $AZN $NEM $RTRX
Pristine Trading
21 Apr 14 06:24:13
ESP Gap Up: $NUS, $NEM, $MNTA, $HD, $AFOP, $RTRX #stockmarket #stocktrading
Brenden Black
21 Apr 14 06:20:08
$RTRX RETROPHIN, INC. Files SEC form 8-K, Other Events, Financial Statem http://t.co/KI2Ok2oogG
Stockaholics
20 Apr 14 23:56:30
Members saw 5,000% gains on Penny Stock Alert's in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Stockaholics
20 Apr 14 18:45:46
Our Penny Stock Newsletter Picks, gained 5,000% in 4 months! Subscribe Today: http://t.co/5B5saivZk0 $RTRX $CPST $TGTX
Donte Dallas
20 Apr 14 18:02:34
$RTRX RETROPHIN, INC. Files SEC form 8-K, Other Events, Financial St http://t.co/pdOrJmirEO
Stock Market Guru
20 Apr 14 11:36:40
$RTRX RETROPHIN, INC. Files SEC form 8-K, Other Events, Financial Statem http://t.co/hJGnZE275V
Scott Spencer
20 Apr 14 11:25:41
$RTRX +18% bottom bounce from $12 to $17.50 with significant risk/reward... http://t.co/YKWUR7E4IN
Stockaholics
20 Apr 14 09:12:00
Our Penny Stock Newsletter Picks, gained 5,000% in 4 months! Subscribe Today: http://t.co/HRvlsV5b8H $RTRX $CPST $TGTX
Boaz Boulstridge
20 Apr 14 08:27:01
$RTRX RETROPHIN, INC. Files SEC form 8-K, Other Events, Financial St http://t.co/aFgaqhZVCr
Fin_Vestor
20 Apr 14 01:14:11
$RTRX Healthcare Weekly Losers: Ultragenyx Pharmaceutical (NASDAQ:RARE ... http://t.co/VgwjK2LXkt
iHugo Albert
19 Apr 14 14:39:34
$RTRX Small Cap Gainers: Retrophin (RTRX), Triangle Petroleum (TPLM), Warren ... http://t.co/VY5rhPTRxW
iHugo Albert
19 Apr 14 12:45:04
$RTRX Worth Watching Stocks - Sangamo Biosciences, Inc (NASDAQ:SGMO), Celldex ... http://t.co/CzR4xqtERp
richardlund
19 Apr 14 12:04:40
RT @bradloncar: Big story on Martin in Businessweek: http://t.co/Cr00S3Q173 $RTRX
iHugo Albert
19 Apr 14 11:54:36
$RTRX Healthcare Weekly Losers: Ultragenyx Pharmaceutical (NASDAQ:RARE ... http://t.co/SQy5UBBQlv
Brice Latimer
19 Apr 14 07:04:15
$RTRX RETROPHIN, INC. Files SEC form 8-K, Other Events, Financial Statem http://t.co/lM9yWOkjqj
				
				
By  +Follow September 19, 2013 8:51AM
Share:

Comments

 

blog comments powered by Disqus

About us

Equities.com is the most advanced interactive online social ecosystem for the financial industry, serving as a resource center and next-generation communication platform that connects self-directed investors with public issuers, market experts, and professional service providers and vendors. Registered members can leverage our exclusive proprietary research tools such as the Small-Cap Stars, which outperformed 90% of all small-cap mutual funds, and robust do-it-yourself E.V.A. research reports. The Equities.com Issuer Dashboard is the ideal tool to communicate and manage investor awareness campaigns to the investment community, as well as to access valuable resources to help your company grow.

Market Data powered by QuoteMedia.
Copyright © QuoteMedia. Data delayed 15 minutes unless otherwise indicated. Terms of Use.